Recombinant human growth hormone vs placebo or no intervention
- Recombinant growth hormone therapy for X‐linked hypophosphatemia in children 2021 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 20 participantsLow
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
It is very uncertain whether summary of findings ‐ recombinant growth hormone changes measures of renal function: change in TmP/GFR compared with placebo or no intervention (very low certainty).
Summary of findings ‐ recombinant growth hormone showed no clear difference in body proportions: sitting height SDS compared with placebo or no intervention (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Dopamine agonist probably leads to lower incidence of moderate or severe OHSS compared with placebo/no intervention (moderate certainty).
It is very uncertain whether dopamine agonist changes incidence of moderate or severe OHSS compared with other active intervention (very low certainty).
Dopamine agonist showed no clear difference in live birth rate compared with other active intervention (low certainty).
Dopamine agonist showed no clear difference in clinical pregnancy rate compared with other active intervention (moderate certainty).
Dopamine agonist showed no clear difference in multiple pregnancy rate compared with other active intervention (low certainty).
Dopamine agonist showed no clear difference in miscarriage rate compared with other active intervention (low certainty).
Dopamine agonist showed no clear difference in live birth rate compared with placebo/no intervention (low certainty).
Dopamine agonist showed no clear difference in clinical pregnancy rate compared with placebo/no intervention (low certainty).